RecruitingNCT07088380
Ketamine added to ECT for treatment-resistant depression
About this title
Read the official source — NCT07088380Medication studyAges 18–70Italy
Understand this study
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.
- Listed locations
- MilanSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: July 10, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 30
- Sponsor
- Università Vita-Salute San Raffaele
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Italy
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT07088380
- Official title
Show the full official title
The Additive Effect of Ketamine in Combination With ElectroConvulsive Stimulation (ECS) in Major Depressive Disorder (MDD): a Translational Study
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Milan
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Università Vita-Salute San Raffaele.
Does this study involve medication?
Yes. The study involves medication, including Ketamine Hydrochloride and Placebo.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
Want to explore more studies?
Explore studiesRelated studies
Samyr injections compared with placebo for depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Compare the Anti-Depressive Efficacy and Safety of Samyr® Tablet versus Placebo Tablet on top of Adjunctive Ant...